{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:50:21Z","timestamp":1781585421641,"version":"3.54.5"},"reference-count":29,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>Introduction:\u00a0In Italy, Non-Hodgkin Lymphomas (NHL), including Waldenstr\u00f6m\u2019s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL), are among the most common hematologic cancers. These conditions mainly affect the elderly, who often have multiple comorbidities, complicating management and imposing significant burdens on patient quality of life and healthcare systems.\nObjective:\u00a0This study aimed to estimate the economic burden of selected B-cell lymphomas in Italy, providing insights for decision-makers to improve patient management and resource allocation.\nMethod:\u00a0Data from the Italian Hospital Discharges Records (SDO) and the National Institute for Social Security were analyzed to estimate direct healthcare costs and social security costs from 2016 to 2019.\nResults:\u00a0A total of 93,712 hospital discharges were recorded, with MZL being the most common diagnosis, followed by CLL and WM. Most patients were male, and the 70\u201379 age group was most prevalent. MZL had the highest costs, followed by CLL and WM. Adverse events notably increased total expenditures, with variations across different pathologies. Direct healthcare costs totaled 533.6 million euros, while social security costs amounted to 240.9 million euros.\nConclusion:\u00a0This study highlights the significant economic burden of selected B-cell lymphomas in Italy. Effective management strategies are crucial for reducing costs and optimizing resource allocation in the healthcare system.<\/jats:p>","DOI":"10.33393\/grhta.2025.3365","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:34:57Z","timestamp":1741707297000},"page":"80-88","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the economic burden of Waldenstr\u00f6m\u2019s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)"],"prefix":"10.33393","volume":"12","author":[{"given":"Matteo","family":"Scortichini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-1308","authenticated-orcid":false,"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1278-604X","authenticated-orcid":false,"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18642","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"15731","doi-asserted-by":"crossref","unstructured":"Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of Non-Hodgkin\u2019s Lymphoma. Vol. 9, Medical sciences (Basel, Switzerland). 2021. DOI: 10.3390\/medsci9010005","DOI":"10.3390\/medsci9010005"},{"key":"15732","doi-asserted-by":"crossref","unstructured":"Mafra A, Laversanne M, Gospodarowicz M, et al. Global patterns of non-Hodgkin lymphoma in 2020. Int J Cancer. 2022;151(9):1474\u20131481. DOI: https:\/\/doi.org\/10.1002\/ijc.34163 PMID:35695282","DOI":"10.1002\/ijc.34163"},{"key":"15733","unstructured":"AIOM AIRTUM. I numeri del cancro in Italia 2023. 2023 Online https:\/\/www.aiom.it\/i-numeri-del-cancro-in-italia\/ (Accessed October 2024)"},{"key":"15734","doi-asserted-by":"crossref","unstructured":"Castillo JJ, Olszewski AJ, Cronin AM, et al. Survival trends in Waldenstr\u00f6m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014;123(25):3999\u20134000. DOI: https:\/\/doi.org\/10.1182\/blood-2014-05-574871 PMID:24948623","DOI":"10.1182\/blood-2014-05-574871"},{"key":"15735","doi-asserted-by":"crossref","unstructured":"Buske C, Leblond V, Dimopoulos M, Kimby E, J\u00e4ger U, Dreyling M. Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24(SUPPL.6). DOI: 10.1093\/annonc\/mdt298","DOI":"10.1093\/annonc\/mdt298"},{"key":"15736","doi-asserted-by":"crossref","unstructured":"Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575\u20131584. DOI: https:\/\/doi.org\/10.1038\/bjc.2015.94 PMID:25867256","DOI":"10.1038\/bjc.2015.94"},{"key":"15737","doi-asserted-by":"crossref","unstructured":"Li S, Liu J, Bowers C, et al. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. Support Care Cancer. 2020;28(1):113\u2013122. DOI: https:\/\/doi.org\/10.1007\/s00520-019-04795-0 PMID:30993450","DOI":"10.1007\/s00520-019-04795-0"},{"key":"15738","doi-asserted-by":"crossref","unstructured":"Kenzik KM, Mehta A, Richman JS, et al. Congestive heart failure in older adults diagnosed with follicular lymphoma: A population-based study. Cancer. 2018;124(21):4221\u20134230. DOI: https:\/\/doi.org\/10.1002\/cncr.31695 PMID:30303522","DOI":"10.1002\/cncr.31695"},{"key":"15739","doi-asserted-by":"crossref","unstructured":"Kenzik KM, Williams GR, Bhakta N, et al. Healthcare utilization and spending among older patients diagnosed with Non-Hodgkin lymphoma. J Geriatr Oncol. 2021;12(8):1225\u20131232. DOI: https:\/\/doi.org\/10.1016\/j.jgo.2021.06.006 PMID:34176753","DOI":"10.1016\/j.jgo.2021.06.006"},{"key":"15740","doi-asserted-by":"crossref","unstructured":"Zakeri M, Li J, Sansgiry SS, et al. Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: analysis of national survey data. J Manag Care Spec Pharm. 2023;29(5):480\u2013489. DOI: https:\/\/doi.org\/10.18553\/jmcp.2023.29.5.480 PMID:37121258","DOI":"10.18553\/jmcp.2023.29.5.480"},{"key":"15741","doi-asserted-by":"crossref","unstructured":"Mounie M, Costa N, Conte C, et al. Costs of Hodgkin and Non-Hodgkin Lymphoma in France: Results on the Basis of the French National Health Insurance Database. Value Health. 2018;21:S25. DOI: https:\/\/doi.org\/10.1016\/j.jval.2018.04.157","DOI":"10.1016\/j.jval.2018.04.157"},{"key":"15742","doi-asserted-by":"crossref","unstructured":"Zucca E, Arcaini L, Buske C, et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.010 PMID:31912792","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"15743","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Smith P, Norton A, et al; British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516\u2013522. DOI: https:\/\/doi.org\/10.1016\/S0140-6736(03)14110-4 PMID:12932382","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"15744","unstructured":"Ministero della Salute. Il flusso informativo SDO. Online https:\/\/www.salute.gov.it\/portale\/assistenzaOspedaliera\/dettaglioContenutiAssistenzaOspedaliera.jsp?lingua=italiano&id=1232&area=ricoveriOspedalieri&menu=rilevazione (Accessed October 2024)"},{"key":"15745","unstructured":"INPS. Osservatorio sulle pensioni erogate dall\u2019INPS. Online https:\/\/servizi2.inps.it\/servizi\/osservatoristatistici\/6 (Accessed October 2024)"},{"key":"15746","doi-asserted-by":"crossref","unstructured":"Russo S, Mariani TT, Migliorini R, et al. The economic burden of musculoskeletal disorders on the Italian social security pension system estimated by a Monte Carlo simulation. Reumatismo. 2015;67(2):45\u201356. DOI: https:\/\/doi.org\/10.4081\/reumatismo.2015.811 PMID:26492962","DOI":"10.4081\/reumatismo.2015.811"},{"key":"15747","doi-asserted-by":"crossref","unstructured":"Cerhan JR, Habermann TM. Epidemiology of marginal zone lymphoma. Ann Lymphoma. 2021;5:5. DOI: https:\/\/doi.org\/10.21037\/aol-20-28 PMID:33829216","DOI":"10.21037\/aol-20-28"},{"key":"15748","doi-asserted-by":"crossref","unstructured":"Sant M, Minicozzi P, Mounier M, et al; EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931\u2013942. DOI: https:\/\/doi.org\/10.1016\/S1470-2045(14)70282-7 PMID:25030467","DOI":"10.1016\/S1470-2045(14)70282-7"},{"key":"15749","doi-asserted-by":"crossref","unstructured":"Darb\u00e0 J, Mars\u00e0 A. Burden of Hodgkin and non-Hodgkin lymphoma in Spain over a 10-year period: productivity losses due to premature mortality. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):87\u201392.DOI: https:\/\/doi.org\/10.1080\/14737167.2020.1769478 PMID:32450710","DOI":"10.1080\/14737167.2020.1769478"},{"key":"15750","doi-asserted-by":"crossref","unstructured":"Cai W, Zeng Q, Zhang X, et al. Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990\u20132019: Results From the Global Burden of Disease Study 2019. Front Med (Lausanne). 2021;8:738693. DOI: https:\/\/doi.org\/10.3389\/fmed.2021.738693 PMID:34631756","DOI":"10.3389\/fmed.2021.738693"},{"key":"15751","doi-asserted-by":"crossref","unstructured":"Miranda-Filho A, Pi\u00f1eros M, Znaor A,et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer Causes Control. 2019;30(5):489\u2013499. DOI: https:\/\/doi.org\/10.1007\/s10552-019-01155-5 PMID:30895415","DOI":"10.1007\/s10552-019-01155-5"},{"key":"15752","doi-asserted-by":"crossref","unstructured":"Rotbain EC, Rostgaard K, Andersen MA, et al. Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia. Clin Epidemiol. 2021;13:1155\u20131165. DOI: https:\/\/doi.org\/10.2147\/CLEP.S337495 PMID:35002328","DOI":"10.2147\/CLEP.S337495"},{"key":"15753","doi-asserted-by":"crossref","unstructured":"Pfeil AM, Imfeld P, Pettengell R, et al. Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD). Ann Hematol. 2015;94(3):421\u2013429. DOI: https:\/\/doi.org\/10.1007\/s00277-014-2217-7 PMID:25219890","DOI":"10.1007\/s00277-014-2217-7"},{"key":"15754","doi-asserted-by":"crossref","unstructured":"Lutz C, Feiten S, Chakupurakal G, et al. Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic. BMC Immunol. 2023;24(1):2. DOI: https:\/\/doi.org\/10.1186\/s12865-022-00536-x PMID:36631764","DOI":"10.1186\/s12865-022-00536-x"},{"key":"15755","doi-asserted-by":"crossref","unstructured":"Johnson PC, Yi A, Horick N, et al. Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma. Oncologist. 2021;26(11):965\u2013973. DOI: https:\/\/doi.org\/10.1002\/onco.13915 PMID:34327767","DOI":"10.1002\/onco.13915"},{"key":"15756","doi-asserted-by":"crossref","unstructured":"Chanan-Khan A, Yang K, Liu S, et al. Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenstr\u00f6m Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Disparities and Risk Factors. Blood. 2021;138(Supplement 1). DOI: 10.1182\/blood-2021-148633","DOI":"10.1182\/blood-2021-148633"},{"key":"15757","doi-asserted-by":"crossref","unstructured":"Kabadi SM, Goyal RK, Nagar SP, et al. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8(8):3803\u20133810. DOI: https:\/\/doi.org\/10.1002\/cam4.2268 PMID:31144473","DOI":"10.1002\/cam4.2268"},{"key":"15758","doi-asserted-by":"crossref","unstructured":"Rosand CB, Valla K, Flowers CR, et al. Effective management strategies for patients with marginal zone lymphoma. Future Oncol. 2018;14(12):1213\u20131222. DOI: https:\/\/doi.org\/10.2217\/fon-2017-0480 PMID:29260925","DOI":"10.2217\/fon-2017-0480"},{"key":"15759","doi-asserted-by":"crossref","unstructured":"Sarosiek S, Treon SP, Castillo JJ. Reducing treatment toxicity in Waldenstr\u00f6m macroglobulinemia. Expert Opin Drug Saf. 2021;20(6):669\u2013676. DOI: https:\/\/doi.org\/10.1080\/14740338.2021.1897565 PMID:33645373","DOI":"10.1080\/14740338.2021.1897565"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3365\/3946","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3365\/3947","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3365\/3948","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3365\/3946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T15:35:19Z","timestamp":1741707319000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/3365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2025.3365","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"value":"2283-5733","type":"electronic"},{"value":"2284-2403","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,11]]}}}